← Human Trials & Peer-Reviewed Studies

Modeling the influence of growth hormone on lipolysis.

Plain-language guide to PMID 12361241 (2002): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Key Facts

PMID
12361241
Journal
Journal of pharmacokinetics and pharmacodynamics
Year
2002
Study type
Randomized Controlled Trial
Authors
Schoemaker RC et al. (5 authors)
DOI
10.1023/a:1019803924485

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Lipolysis (the breakdown of fat) is generally estimated using stable isotopes, where the rate of appearance (Ra) of glycerol is calculated using Steele's equations.

These equations are based on single-compartment differential equations for tracer and tracee where rate of change is approximated by the change in concentration from one time point to the next.

How the Study Was Run

In design terms this was a randomized, double-blind and crossover study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

In the crossover set-up each of the participants took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.

What Was Measured

The subject headings attached to it are Glycerol, Growth Hormone, Lipolysis, Models, Biological and Obesity.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 2002 (Journal of pharmacokinetics and pharmacodynamics), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.